Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8952W HIGH $1.75
Volume
64.65 K
Value Traded
43.34 K
Short % Float
2.23%
-7.44%Week
-4.27%1 Month
-9.68%3 Month
-13.85%6 Month
-81.57%5 Year
-81.57%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
77.03 M
EPS (TTM)
-0.09
P/E Ratio
-
Ent. Value
71.86 M
Total Shares
68.72 M
Float Shares
34.80 M
Insiders
49.40%
Institutions
4.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TELO Catalyst Timeline
Dated clinical, regulatory and corporate events for Telomir Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Telomir Pharmaceuticals, Inc.
53Total events
5Upcoming
1Tier-1 (high impact)
2024 to 2027Coverage
Upcoming catalysts 2
Event history 43
▲Additional DataTELO-MRDClinical Data
Additional clinical research results comparing blood-based TELO-MRD with bone-marrow NGS (clonoSEQ)
multiple myelomasource ↗
▲PublicationTelomir-ZnPresentation
Peer-reviewed publication of preclinical data showing Telomir-Zn restores visual function and retinal structure in AMD model
age-related macular degeneration (AMD)source ↗
▲Additional DataTELO-MRDClinical Data
TELO-MRD detected residual myeloma cells in 92.9% of matched samples vs 54.8% by EuroFlow NGF in University of Athens retrospective collaboration
multiple myelomasource ↗
▲Preclinical PoCTelomir-ZnPreclinical
Telomir-Zn shows inhibition of cell growth in human and canine osteosarcoma models in vitro
osteosarcomasource ↗
▲PublicationTelomir-ZnPresentation
Peer-reviewed publication of preclinical data for Telomir-Zn
prostate and triple-negative breast cancer (TNBC)source ↗
◆Oral PresentationTelomir-ZnPresentation
Presentation at BIO International Convention
cancer and agingsource ↗
▲PublicationTelomir-ZnPresentation
Peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity with Telomir-Zn in a diet-induced zebrafish model of T2DM
Type 2 diabetes mellitussource ↗
▲IND ClearanceTelomir-ZnIND
FDA IND clearance for Phase 1/2 clinical trial in advanced or metastatic triple-negative breast cancer
Triple-negative breast cancersource ↗
▲PublicationTelomir-ZnPresentation
Peer-reviewed publication of Telomir-Zn preclinical data in Wilson's disease model in Advances in Redox Research
Wilson's diseasesource ↗
▲IND ClearanceTelomir-1IND
FDA IND clearance for Phase 1/2 trial in Triple-Negative Breast Cancer
Triple-Negative Breast Cancersource ↗
◆Oral PresentationTelomir-ZnPresentation
Presentation at 16th World Congress on Breast Cancer Research & Therapies
breast cancersource ↗
▲Preclinical PoCTelomir-1Preclinical
Telomir-1 demonstrates iron-dependent tumor cell mortality in human TNBC cell lines
triple-negative breast cancersource ↗
▲Preclinical PoCTelomir-ZnPreclinical
New cellular data showing Telomir-Zn modulates intracellular zinc and iron
cancer and agingsource ↗
▲Preclinical PoCTelomir-1Preclinical
Telomir-1 demonstrated statistically significant reductions in primary tumor growth and metastatic dissemination in TNBC animal models
triple-negative breast cancersource ↗
●IND SubmissionTelomir-1IND
IND submission for Telomir-1 planned in Q1 2026
triple-negative breast cancersource ↗
●IND SubmissionTelomir-ZnIND
IND application submission planned for Telomir-Zn
cancer and agingsource ↗
◆IND SubmissionTelomir-1IND
Anticipated submission of animal IND (AIND) for veterinary trials
age-related conditions (veterinary)source ↗
◆Trial InitiationTelomir-1Trial
Anticipated initiation of veterinary clinical trials
age-related conditions (veterinary)source ↗
◆IND SubmissionTelomir-1IND
Anticipated submission of human IND for osteoarthritis
osteoarthritissource ↗
◆Trial InitiationTelomir-1Trial
Anticipated initiation of human clinical trials for osteoarthritis
osteoarthritissource ↗
●Oral PresentationPresentation
Scientific advisor participates in DIA 2024 panel on generative AI in clinical trials
▲First Patient DosedTelomir-1Trial
First dosing of Telomir-1 in geriatric canine study
age-related conditionssource ↗
▲Enrollment UpdateTelomir-1Trial
Enrollment of 5 geriatric beagle dogs (4 active, 1 placebo)
age-related conditionssource ↗
▲First Patient DosedTelomir-1Trial
Dosing of Zeus, a geriatric German Shepherd, with Telomir-1
age-related conditionssource ↗
◆Oral PresentationTelomir-1Presentation
Presentation of pre-clinical data for Telomir-1 at National Press Club
age-related conditionssource ↗
▲Preclinical PoCTelomir-1Preclinical
Telomir-1 demonstrated 40% increase in telomerase activity and telomere elongation in human cells in vitro
age-related conditionssource ↗
◆Trial InitiationTelomir-1Trial
Collaboration with Argenta to begin canine osteoarthritis study
osteoarthritis in caninessource ↗
◆Trial InitiationTelomir-1Trial
Collaboration with Argenta to begin canine osteoarthritis study
osteoarthritis in caninessource ↗
◆Poster PresentationTelomir-1Presentation
Poster presentation at Global Longevity Federation Conference
age-related conditionssource ↗
◆Oral PresentationTelomir-1Presentation
Presentation at Global Longevity Federation in Las Vegas
age-related conditionssource ↗
▲Partnership / LicenseTelomir-1Corporate
Collaboration with InSilicoTrials for AI modeling on Telomir-1
◆Poster PresentationTelomir-1Presentation
Poster presentation at NUHS Centre for Healthy Longevity Conference 2024 showing Telomir-1 effect on telomere length in human cell lines
age-related conditionssource ↗
▲Preclinical PoCTelomir-1Preclinical
Pre-clinical data demonstrating Telomir-1 induces telomere extensions in primary human cell strains
age-related conditionssource ↗
▲Oral PresentationTelomir-1Presentation
AI-powered research presented in Singapore last month
age-related conditionssource ↗
◆IND Enabling CompleteTelomir-1Preclinical
Anticipated completion of pre-clinical IND-enabling studies in animals
age-related conditionssource ↗
◆Timing GuidanceTelomir-1Presentation
Additional data expected to be presented to longevity community in coming months
age-related conditionssource ↗
Past FDA Catalysts and PDUFA Decisions
How TELO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-06 | Telomir-1 (Telomir-Zn) | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$8M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 92%
Micro Cap(rank 605 of 657)
Percentile Rank
Telomir Pharmaceuticals, Inc. faces pipeline headwinds (21/100), with $190M risk-adjusted pipeline value, led by Zn-Telomir in Triple-Negative Breast Cancer (TNBC) (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zn-Telomir Small moleculeNCT07581314 | Triple-Negative Breast Cancer (TNBC) | Phase 1 | NOT YET_RECRUITING | 76 | Nov 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every TELO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Telomir-1 | triple-negative breast cancer | 2026-01-05 | statistically significant reductions in primary tumor growth; statistically significant activity on both tumor growth and cancer cell spread; greater tumor growth inhibition than either agent aloneRead More | Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal ModelsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Aminov ErezDirector, Officer (CEO and Chairman) | Grant/Award | 1,960,170 1,960,170 held | $0.00 | 05/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TELO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TELO for Q2 2026. | ||||
TELO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TELO ranks across every disease it competes in
Competitive Position is a premium feature
See how TELO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTELO News
TELOTelomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Telomir Pharmaceuticals has announced a $5.6 million PIPE financing, including a $1 million investment from billionaire John Paul DeJoria. This funding will support the clinical development of Telomir-Zn, which has received FDA clearance for its Phase 1/2 trial targeting advanced or metastatic triple-negative breast cancer. The company aims to use the proceeds to advance its lead program and enhance shareholder value.
Read more →TELOTelo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
Telo Genomics has reported promising results from its TELO-MRD program, which compares blood-based testing for Minimal Residual Disease (MRD) in multiple myeloma patients against traditional bone marrow methods. The study indicates that TELO-MRD detected circulating myeloma cells in a higher percentage of samples than bone marrow tests. However, the findings are preliminary and based on a limited dataset, necessitating further validation before clinical application.
Read more →TELOTelomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
Telomir Pharmaceuticals announced a peer-reviewed publication detailing preclinical research on Telomir-Zn. The study demonstrated significant improvements in visual function and retinal structure in a model of age-related macular degeneration (AMD). Additionally, it showed a reduction in mitochondrial oxidative stress, highlighting the potential of Telomir-Zn as a therapeutic option.
Read more →TELOTelo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse
Telo Genomics reported promising clinical research results for its TELO-MRD assay, which detected residual myeloma cells more effectively than traditional bone marrow methods. The assay combines blood-based detection with three-dimensional telomere profiling to assess relapse risk in multiple myeloma patients. While results are encouraging, further validation in larger studies is necessary before commercialization.
Read more →TELOTelomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Telomir Pharmaceuticals has announced promising research findings from The Ohio State University, showing that their compound Telomir-Zn inhibits cell growth in both human and canine osteosarcoma models. This research supports the potential for further evaluation of Telomir-Zn as a therapeutic option. The collaboration highlights the company's commitment to advancing cancer treatment.
Read more →TELO3rd International Conference on Women’s Health and Breast Cancer
The article announces the 3rd International Conference on Women’s Health and Breast Cancer. It highlights the event's focus on women's health issues, particularly breast cancer. The conference aims to bring together experts in the field to discuss advancements and challenges. Further details about the conference are not provided.
Read more →TELOQ2 Quarterly results 2026
Telomir Pharmaceuticals, Inc. (TELO) has released its Q2 quarterly results for 2026. The report is available in both PDF and DOCX formats. Further details regarding the financial performance and operational highlights are expected to be outlined in the report.
Read more →TELOTelomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Telomir Pharmaceuticals has announced a peer-reviewed publication showcasing the effectiveness of Telomir-Zn in suppressing tumor growth in models of triple-negative breast cancer (TNBC) and prostate cancer. The study highlights the compound's ability to selectively modulate intracellular iron and copper levels, suggesting a novel approach to cancer treatment. This publication adds credibility to Telomir's ongoing research efforts.
Read more →TELOTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Telomir Pharmaceuticals has announced the publication of preclinical data in the journal 'Biomedicine & Pharmacotherapy,' demonstrating that Telomir-Zn restores insulin sensitivity in a zebrafish model of Type 2 diabetes. The study showed significant improvements in glucose metabolism and insulin resistance following 14 days of treatment. This reinforces the evidence supporting Telomir-Zn's mechanism of action geared towards correcting intracellular metal homeostasis, which is implicated in metabolic diseases. The findings contribute to Telomir's development of Telomir-Zn as a therapeutic candidate for conditions such as Type 2 diabetes and triple-negative breast cancer.
Read more →TELO▲ +7.4%on this news
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved
Telomir Pharmaceuticals, Inc. announced the peer-reviewed publication of data regarding Telomir-Zn, showcasing its effectiveness in improving survival rates and multiple endpoints in a preclinical model of Wilson's disease. The published study highlighted significant benefits, including reduced hepatic copper burden, enhanced liver biomarkers, and improved locomotor function. Importantly, the findings underscore the therapeutic potential of Telomir-Zn in addressing the oxidative stress and mitochondrial dysfunction associated with Wilson's disease. This marks a significant scientific milestone for Telomir, aligning with the ongoing development of their lead program for Triple-Negative Breast Cancer.
Read more →TELO▲ +5.5%on this news
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
Telomir Pharmaceuticals announced promising in vitro data showing that its compound, Telomir-Zn, induces significant tumor cell mortality across various subtypes of triple-negative breast cancer (TNBC). The mechanism is linked to iron modulation, with studies confirming that tumor cell death is iron-dependent. The company is preparing for an Investigational New Drug submission in early 2026, following successful preclinical results.
Read more →TELOTelomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Telomir Pharmaceuticals has reported new findings on Telomir-Zn, demonstrating its ability to modulate intracellular metal balance, which is linked to oxidative stress and genomic integrity. The study shows that Telomir-Zn increases zinc levels while reducing redox-active iron, suggesting a novel mechanism for addressing cancer and aging. The company plans to present these findings at several upcoming scientific meetings.
Read more →TELO▲ +11.2%on this news
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
Telomir Pharmaceuticals announced that Telomir-1 showed significant efficacy in reducing tumor growth and metastasis in aggressive triple-negative breast cancer (TNBC) animal models. The study highlighted that Telomir-1, both alone and in combination with paclitaxel, effectively inhibited tumor growth in models with varying chemotherapy responsiveness. These findings underscore the potential for personalized treatment strategies in TNBC.
Read more →TELO▲ +15.6%on this news
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman
Telomir Pharmaceuticals announced the passing of its Chairman and CEO, Dr. Christopher Chapman. In light of this loss, Erez Aminov has been appointed as the new CEO and Chairman. The company also experienced changes in its Board of Directors, with several resignations and new appointments. The leadership transition comes as Telomir continues its focus on developing Telomir-1 for age-related conditions.
Read more →TELOTelomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
Telomir Pharmaceuticals has been added to the Russell 3000 and Russell Microcap Indexes, effective July 1, 2024. This inclusion highlights the company's growth since its IPO and positions it for further success in developing Telomir-1, a novel treatment aimed at age-related conditions. The Russell indexes are significant benchmarks for investment strategies.
Read more →TELOTelomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
Telomir Pharmaceuticals announced that its scientific advisor, Dr. Adam Kaplin, will participate in a panel at the DIA Global Annual Meeting on June 17, 2024. The panel will focus on the use of generative AI in clinical trials, aiming to improve efficiency and safety in drug development. This opportunity showcases Telomir's commitment to leveraging innovative technologies in its research.
Read more →TELO▼ -7.6%on this news· ran to -18% by day 3
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
Telomir Pharmaceuticals has initiated pivotal studies for its lead product candidate, Telomir-1, focusing on its safety and efficacy in geriatric canines. The study commenced on May 28, 2024, with initial doses well-tolerated by the animals. This research aims to provide insights into treating age-related conditions, potentially benefiting both pets and humans.
Read more →TELOTelomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support
Telomir Pharmaceuticals, Inc. has signed a media deal with New to The Street to feature its management in interviews and advertisements aimed at promoting its TELOMIR-1 drug, which targets age-related diseases. This agreement includes broadcasts on Bloomberg TV and the FOX Business Network, alongside digital advertising across New York City. The company is in the pre-clinical stage of developing TELOMIR-1, which aims to reverse age-related inflammation conditions. Management expresses optimism regarding the drug's potential and the increased exposure from the media partnership.
Read more →TELO▼ -5.3%on this news
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir Pharmaceuticals presented promising pre-clinical data on its age-reversal drug, Telomir-1, at a National Press Club event. The drug showed a 40% increase in telomerase activity and lengthened telomeres in vitro. The company plans to initiate human and animal trials for osteoarthritis in 2025, highlighting its commitment to addressing age-related conditions.
Read more →TELOTelomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Telomir Pharmaceuticals announced that Dr. Michael F. Roizen will present pre-clinical data for Telomir-1, a drug aimed at reversing age-related conditions, at the National Press Club on April 15, 2024. The data suggests that Telomir-1 may elongate telomeres, potentially stimulating stem cell renewal. The event aims to share findings with the public and the longevity community.
Read more →About Telomir Pharmaceuticals, Inc.
Headquarters100 SE 2ND ST, MIAMI, FL, 33131
BIOPHARMAWATCH ELITE PLUS
Trade the next TELO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime